ReviewJournal of the Endocrine Society2025
Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk.
Review in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Delayed gastric emptying caused by glucagon-like peptide-1 receptor agonists (GLP-1RAs) has raised concerns about increased aspiration risk during surgical and endoscopic procedures. In June 2023, the American Society of Anesthesiologists (ASA) recommended discontinuing GLP-1RAs one day (daily users) or one week (weekly users) before elective surgery or endoscopic esophagogastroduodenoscopy (EGD). In October 2024, the ASA reversed the initial recommendation and advised most patients to continue taking GLP-1RAs before elective surgery. Objective: We conducted a systematic review of the evidence for or against the original recommendation. Methods: We searched PubMed for retrospective cohort studies published between June 2023 and March 2025 investigating the association between GLP-1RA use and the risk of aspiration/pneumonia in patients undergoing elective surgery or endoscopic procedures. We calculated a summary risk ratio for studies that could be combined. Results: We identified 3 studies of elective surgery and 4 of EGD using large databases to identify an increased risk of aspiration/pneumonia associated with GLP-1RA use. The 3 elective surgery studies had a combined risk ratio of 1.00 [0.76, 1.30]. The 4 EGD studies had a combined risk ratio of 1.10 [0.95, 1.27]. In one study, a parallel analysis of the aspiration/pneumonia risk associated with opioid medications found a risk ratio of 2.68 [1.89, 3.81], indicating that the methodology could detect an increased risk of aspiration/pneumonia from a motility inhibitor. Conclusion: Although GLP-1RAs cause delayed gastric emptying, retrospective cohort studies using large real-world evidence databases have not consistently identified a GLP-1RA-associated risk of aspiration/pneumonia for elective surgical and endoscopic procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.